Skip to main
QNCX

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics is well positioned for success with their novel drug/device combination therapy, eDSP, as seen in the promising results from the ATTeST trial and the potential for expansion into other rare diseases. However, the recent failure in the Phase 3 NEAT trial has caused a significant drop in the company's stock price. Further exploration of options and a conservative approach to cash management may lead to a rebound in the stock value in the future.

Bears say

Quince Therapeutics is facing significant risks, as their only pipeline candidate, eDSP, has shown disappointing results in the Phase 3 ATTeST trial for A-T. This raises concern about the drug's efficacy and the potential for further market share and valuation erosion. Additionally, the company's lack of approved drugs and limited visibility into its strategic roadmap may keep investor sentiment subdued. The success of their eDSP program in the ongoing Phase 3 NEAT trial will be critical to their future success and ability to raise additional capital.

QNCX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 2 analysts, QNCX has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.